Addiction Treatment Center Pathway Healthcare’s Chief Medical Officer Appointed to ASAM’s 2019 Board of Directors

Addiction Treatment Center Pathway Healthcare’s Chief Medical Officer Appointed to ASAM’s 2019 Board of Directors

Dr. Brent Boyett Joins ASAM’s Prestigious Board of Directors, Which Represents More Than 6,000 Addiction Medicine Professionals

BIRMINGHAM, Ala. ( June 3, 2019)

Pathway Healthcare, a leading provider of office-based medical and behavioral treatment for drug and alcohol addiction and dependency, announced today that its Chief Medical Officer, Dr. Brent Boyett, has been appointed to the Board of Directors for the American Society of Addiction Medicine (ASAM). The board is comprised of the nation’s most knowledgeable physicians in addiction medicine and is poised to lead the battle against today’s addiction crisis.

Joining the board alongside an impressive lineup of physicians, Dr. Boyett is one of the nation’s few board-certified addiction medicine specialists and current Chief Medical Officer with Pathway Healthcare, where he uses medication-assisted treatment (MAT) to help patients suffering from substance use disorders.

“It is a privilege to be named to ASAM’s 2019 Board of Directors, and I am humbled to have access to yet another platform that will allow me to further educate both the medical community and the public on effective addiction treatment methods, such as MAT,” said Dr. Boyett. “I am excited to work with ASAM to increase access to evidence-based treatment, prioritizing efforts to train doctors and standardize addiction treatment. As healthcare professionals, we must do everything we can to curb the nation’s drug crisis, and break the stigma associated with drug and alcohol addiction.”

In addition to serving as Pathway Healthcare’s Chief Medical Officer, Dr. Boyett is also a renowned researcher and thought leader. He has served as a clinical advisor for the pharmaceutical industry to aid in the development of new treatment options and as a principal investigator in several clinical trials, including the U.S. Food and Drug Administration (FDA)’s approval for injectable buprenorphine. Dr. Boyett is also the current president of the Alabama Society of Addiction Medicine (ALSAM), working to further implement addiction medicine into mainstream healthcare.

“We are proud to have Dr. Boyett as our Chief Medical Officer,” said Scott Olson, CEO of Pathway Healthcare. “He has dedicated his career to helping those suffering from substance use disorders receive the best treatment, and I am confident that he will continue to make valuable inroads in the addiction space. I look forward to seeing what he accomplishes as part of ASAM’s Board of Directors.”

Pathway Healthcare currently has 12 office locations spanning Alabama, Mississippi, Texas, and Tennessee, with plans to open its newest office in Athens, AL this summer. The addiction treatment center specializes in treating substance use disorders through a proprietary care model, known as MAT Plus®, which combines medication-assisted treatment with behavioral counseling.

About Pathway Healthcare

Pathway Healthcare, LLC is a team of specialists committed to helping patients suffering from drug and alcohol addiction and dependency. Pathway’s proprietary MAT Plus® program combines medication-assisted treatment and behavioral counseling in a professional and convenient office-based, outpatient setting. Learn more at www.pathwayhealthcare.com.

About American Society of Addiction Medicine (ASAM)

ASAM, founded in 1954, is a professional medical society representing over 6,000 physicians, clinicians and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction. Learn more at https://www.asam.org/.